Purpose: Although biochemical parameters have always been the basis for assessing acromegaly disease activity, other factors such as symptoms and comorbidities should also be considered. To assist clinicians in diagnosis and follow-up both the Acromegaly Disease Activity Tool (ACRODAT®) and SAGIT® (Signs and Symptoms, Associated morbidity, GH, IGF-1, Tumor) instrument were developed. This study aimed to evaluate the real-life utility of ACRODAT® and SAGIT® in assessing acromegaly disease activity across four centers of Veneto region in north-east Italy. Methods: 162 patients were enrolled in this multicenter study. Patients’ disease activity was classified by: clinician’s judgment categories (A: active disease; MA: mild activity; CO: controlled disease; CU: cured), ACRODAT® (green: well-controlled, yellow: partially controlled, red: active), and SAGIT® (lower scores indicate better control). The disease activity data derived from these methods were compared. Results: The four centers showed similar results in terms of acromegaly disease-related data. ACRODAT® categorized 48% of patients as well-controlled, 28% as partially-controlled, and 24% as active. 48% of patients had a SAGIT® score below the median number of 7. The SAGIT® trend in the population subdivided by ACRODAT® categories showed significant lower SAGIT® scores in well-controlled patients compared to partially-controlled or active patients (well-controlled: 5.6 ± 2.3, partially-controlled: 7.0 ± 3.05, active: 8.3 ± 2.4; p < 0.001). According to the clinician’s judgement, 62% of patients had controlled disease; indeed, both ACRODAT® and SAGIT® scores differed significantly among the four categories of clinician’s judgement. Conclusions: Both ACRODAT® and SAGIT® instrument effectively assessed disease activity in acromegaly, without discrepancy with the expert clinician’s judgment. These tools provide a valuable aid in acromegaly management and could allow non-expert endocrinologists to assess disease activity accurately.
ACRODAT and SAGIT for the assessment of disease activity in acromegaly: a multicenter study of the Veneto region in Italy
Dassie, Francesca;Ceccato, Filippo;Sartorato, Paola;Scaroni, Carla;Maffei, Pietro
2025
Abstract
Purpose: Although biochemical parameters have always been the basis for assessing acromegaly disease activity, other factors such as symptoms and comorbidities should also be considered. To assist clinicians in diagnosis and follow-up both the Acromegaly Disease Activity Tool (ACRODAT®) and SAGIT® (Signs and Symptoms, Associated morbidity, GH, IGF-1, Tumor) instrument were developed. This study aimed to evaluate the real-life utility of ACRODAT® and SAGIT® in assessing acromegaly disease activity across four centers of Veneto region in north-east Italy. Methods: 162 patients were enrolled in this multicenter study. Patients’ disease activity was classified by: clinician’s judgment categories (A: active disease; MA: mild activity; CO: controlled disease; CU: cured), ACRODAT® (green: well-controlled, yellow: partially controlled, red: active), and SAGIT® (lower scores indicate better control). The disease activity data derived from these methods were compared. Results: The four centers showed similar results in terms of acromegaly disease-related data. ACRODAT® categorized 48% of patients as well-controlled, 28% as partially-controlled, and 24% as active. 48% of patients had a SAGIT® score below the median number of 7. The SAGIT® trend in the population subdivided by ACRODAT® categories showed significant lower SAGIT® scores in well-controlled patients compared to partially-controlled or active patients (well-controlled: 5.6 ± 2.3, partially-controlled: 7.0 ± 3.05, active: 8.3 ± 2.4; p < 0.001). According to the clinician’s judgement, 62% of patients had controlled disease; indeed, both ACRODAT® and SAGIT® scores differed significantly among the four categories of clinician’s judgement. Conclusions: Both ACRODAT® and SAGIT® instrument effectively assessed disease activity in acromegaly, without discrepancy with the expert clinician’s judgment. These tools provide a valuable aid in acromegaly management and could allow non-expert endocrinologists to assess disease activity accurately.
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
